Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis, Role of Immunosenescence

  • Dema, María|||0000-0003-4812-4304
  • Eixarch, Herena|||0000-0001-7525-9533
  • Hervera Abad, Arnau|||0000-0001-8362-369X
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability accumulation. This phenomenon can be related to age-related changes in the immune system: with age, the immune system undergoes a process called immunosenescence, characterized by a decline in the function of both the innate and adaptive immune responses. This decline can lead to a decreased ability to control inflammation and repair damaged tissue. Additionally, older individuals often experience a shift toward a more pro-inflammatory state, known as inflammaging, which can exacerbate the progression of neurodegenerative diseases like MS. Therefore, age-related alterations in the immune system could be responsible for the difference in the phenotype of MS observed in older and younger patients. In this study, we investigated the effects of age on the immunopathogenesis of experimental autoimmune encephalomyelitis (EAE). Our findings indicate that EAE is more severe in aged mice due to a more inflammatory and neurodegenerative environment in the central nervous system. Age-related changes predominantly affect adaptive immunity, characterized by altered T cell ratios, a pro-inflammatory Th1 response, increased regulatory T cells, exhaustion of T cells, altered B cell antigen presentation, and reduced NK cell maturation and cytotoxicity. Transcriptomic analysis reveals that fewer pathways and transcription factors are activated with age in EAE. These findings allow us to identify potential therapeutic targets specific to elderly MS patients and work on their development in the future.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis

  • Dema Etxezarreta, María
  • Eixarch, Herena
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Montalban, Xavier
Ageing; Immunosenescence; Multiple sclerosis, Envelliment; Immunosenescència; Esclerosi múltiple, Envejecimiento; Inmunosenescencia; Esclerosis múltiple, Multiple sclerosis (MS) onset at an advanced age is associated with a higher risk of developing progressive forms and a greater accumulation of disability for which there are currently no effective disease-modifying treatments. Immunosenescence is associated with the production of the senescence-associated secretory phenotype (SASP), with IL-6 being one of the most prominent cytokines. IL-6 is a determinant for the development of autoimmunity and neuroinflammation and is involved in the pathogenesis of MS. Herein, we aimed to preclinically test the therapeutic inhibition of IL-6 signaling in experimental autoimmune encephalomyelitis (EAE) as a potential age-specific treatment for elderly MS patients. Young and aged mice were immunized with myelin oligodendrocyte protein (MOG)35–55 and examined daily for neurological signs. Mice were randomized and treated with anti-IL-6 antibody. Inflammatory infiltration was evaluated in the spinal cord and the peripheral immune response was studied. The blockade of IL-6 signaling did not improve the clinical course of EAE in an aging context. However, IL-6 inhibition was associated with an increase in the peripheral immunosuppressive response as follows: a higher frequency of CD4 T cells producing IL-10, and increased frequency of inhibitory immune check points PD-1 and Tim-3 on CD4+ T cells and Lag-3 and Tim-3 on CD8+ T cells. Our results open the window to further studies aimed to adjust the anti-IL-6 treatment conditions to tailor an effective age-specific therapy for elderly MS patients., This work was funded by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III and co-funded by the European Union (European Regional Development Fund/European Social Fund) “A way to build Europe” under Grant [PI18/01146] and the “Agència de Gestió d’Ajuts Universitaris i de Recerca” (AGAUR; Generalitat de Catalunya) under Grant [2021SGR782].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunosenescence in multiple sclerosis: the identification of new therapeutic targets

  • Dema Etxezarreta, Maria Arantza
  • Eixarch Ahufinger, Herena
  • Villar, Luisa M
  • Montalban Gairín, Xavier
  • Espejo Ruiz, Carmen
Autoimmunitat; Immunosenescència; Esclerosi múltiple, Autoinmunidad; Inmunosenescencia; Esclerosis múltiple, Autoimmunity; Immunosenescence; Multiple sclerosis, The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase in the life expectancy of the general population and the availability of effective disease-modifying treatments. However, current treatments reduce the frequency of relapses and slow the progression of the disease, but they cannot stop the disability accumulation associated with disease progression. One possible explanation is the impact of immunosenescence, which is associated with the accumulation of unusual immune cell subsets that are thought to have a role in the development of an early ageing process in autoimmunity. Here, we provide a recent overview of how senescence affects immune cell function and how it is involved in the pathogenesis of autoimmune diseases, particularly MS. Numerous studies have demonstrated age-related immune changes in experimental autoimmune encephalomyelitis models, and the premature onset of immunosenescence has been demonstrated in MS patients. Therefore, potential therapeutic strategies based on rejuvenating the immune system have been proposed. Senolytics and regenerative strategies using haematopoietic stem cells, therapies based on rejuvenating oligodendrocyte precursor cells, microglia and monocytes, thymus cells and senescent B and T cells are capable of reversing the process of immunosenescence and could have a beneficial impact on the progression of MS., This work was supported by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III , and co-funded by the European Union ( European Regional Development Fund / European Social Fund ), “A way to build Europe”, under Grant PI18/01146 and RD16/0015/004 and the “ Agència de Gestió d'Ajuts Universitaris i de Recerca ” (AGAUR; Generalitat de Catalunya ) under Grant 2017SGR527 .
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence

  • Hervera Abad, Arnau
  • Dema Etxezarreta, María
  • Eixarch, Herena
  • Castillo Juárez, Mireia
  • Villar, Luisa M
  • Espejo, Carmen
  • Montalban, Xavier
Adaptive immunity; Experimental autoimmune encephalomyelitis; Neurodegeneration, Immunitat adaptativa; Encefalomielitis autoimmune experimental; Neurodegeneració, Inmunidad adaptativa; Encefalomielitis autoinmune experimental; Neurodegeneración, The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability accumulation. This phenomenon can be related to age-related changes in the immune system: with age, the immune system undergoes a process called immunosenescence, characterized by a decline in the function of both the innate and adaptive immune responses. This decline can lead to a decreased ability to control inflammation and repair damaged tissue. Additionally, older individuals often experience a shift toward a more pro-inflammatory state, known as inflammaging, which can exacerbate the progression of neurodegenerative diseases like MS. Therefore, age-related alterations in the immune system could be responsible for the difference in the phenotype of MS observed in older and younger patients. In this study, we investigated the effects of age on the immunopathogenesis of experimental autoimmune encephalomyelitis (EAE). Our findings indicate that EAE is more severe in aged mice due to a more inflammatory and neurodegenerative environment in the central nervous system. Age-related changes predominantly affect adaptive immunity, characterized by altered T cell ratios, a pro-inflammatory Th1 response, increased regulatory T cells, exhaustion of T cells, altered B cell antigen presentation, and reduced NK cell maturation and cytotoxicity. Transcriptomic analysis reveals that fewer pathways and transcription factors are activated with age in EAE. These findings allow us to identify potential therapeutic targets specific to elderly MS patients and work on their development in the future., This work was supported by the Fondo de Investigaciónes Sanitarias, Instituto de Salud Carlos III, and co-funded by the European Union (European Regional Development Fund/European Social Fund), “A way to build Europe”, under Grant PI18/01146 and the “Agència de Gestió d'Ajuts Universitaris i de Recerca” (AGAUR; Generalitat de Catalunya) under Grant 2021SGR782.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunosenescence in multiple sclerosis, the identification of new therapeutic targets

  • Dema, María|||0000-0003-4812-4304
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase in the life expectancy of the general population and the availability of effective disease-modifying treatments. However, current treatments reduce the frequency of relapses and slow the progression of the disease, but they cannot stop the disability accumulation associated with disease progression. One possible explanation is the impact of immunosenescence, which is associated with the accumulation of unusual immune cell subsets that are thought to have a role in the development of an early ageing process in autoimmunity. Here, we provide a recent overview of how senescence affects immune cell function and how it is involved in the pathogenesis of autoimmune diseases, particularly MS. Numerous studies have demonstrated age-related immune changes in experimental autoimmune encephalomyelitis models, and the premature onset of immunosenescence has been demonstrated in MS patients. Therefore, potential therapeutic strategies based on rejuvenating the immune system have been proposed. Senolytics and regenerative strategies using haematopoietic stem cells, therapies based on rejuvenating oligodendrocyte precursor cells, microglia and monocytes, thymus cells and senescent B and T cells are capable of reversing the process of immunosenescence and could have a beneficial impact on the progression of MS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis

  • Dema, María|||0000-0003-4812-4304
  • Eixarch, Herena|||0000-0001-7525-9533
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
Multiple sclerosis (MS) onset at an advanced age is associated with a higher risk of developing progressive forms and a greater accumulation of disability for which there are currently no effective disease-modifying treatments. Immunosenescence is associated with the production of the senescence-associated secretory phenotype (SASP), with IL-6 being one of the most prominent cytokines. IL-6 is a determinant for the development of autoimmunity and neuroinflammation and is involved in the pathogenesis of MS. Herein, we aimed to preclinically test the therapeutic inhibition of IL-6 signaling in experimental autoimmune encephalomyelitis (EAE) as a potential age-specific treatment for elderly MS patients. Young and aged mice were immunized with myelin oligodendrocyte protein (MOG) and examined daily for neurological signs. Mice were randomized and treated with anti-IL-6 antibody. Inflammatory infiltration was evaluated in the spinal cord and the peripheral immune response was studied. The blockade of IL-6 signaling did not improve the clinical course of EAE in an aging context. However, IL-6 inhibition was associated with an increase in the peripheral immunosuppressive response as follows: a higher frequency of CD4 T cells producing IL-10, and increased frequency of inhibitory immune check points PD-1 and Tim-3 on CD4 + T cells and Lag-3 and Tim-3 on CD8 + T cells. Our results open the window to further studies aimed to adjust the anti-IL-6 treatment conditions to tailor an effective age-specific therapy for elderly MS patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Disease Aggravation With Age in an Experimental Model of Multiple Sclerosis: Role of Immunosenescence

  • Hervera Abad, Arnau
  • Dema Etxezarreta, María
  • Eixarch, Herena
  • Castillo Juárez, Mireia
  • Villar, Luisa M
  • Espejo, Carmen
  • Montalban, Xavier
Adaptive immunity; Experimental autoimmune encephalomyelitis; Neurodegeneration, Immunitat adaptativa; Encefalomielitis autoimmune experimental; Neurodegeneració, Inmunidad adaptativa; Encefalomielitis autoinmune experimental; Neurodegeneración, The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability accumulation. This phenomenon can be related to age-related changes in the immune system: with age, the immune system undergoes a process called immunosenescence, characterized by a decline in the function of both the innate and adaptive immune responses. This decline can lead to a decreased ability to control inflammation and repair damaged tissue. Additionally, older individuals often experience a shift toward a more pro-inflammatory state, known as inflammaging, which can exacerbate the progression of neurodegenerative diseases like MS. Therefore, age-related alterations in the immune system could be responsible for the difference in the phenotype of MS observed in older and younger patients. In this study, we investigated the effects of age on the immunopathogenesis of experimental autoimmune encephalomyelitis (EAE). Our findings indicate that EAE is more severe in aged mice due to a more inflammatory and neurodegenerative environment in the central nervous system. Age-related changes predominantly affect adaptive immunity, characterized by altered T cell ratios, a pro-inflammatory Th1 response, increased regulatory T cells, exhaustion of T cells, altered B cell antigen presentation, and reduced NK cell maturation and cytotoxicity. Transcriptomic analysis reveals that fewer pathways and transcription factors are activated with age in EAE. These findings allow us to identify potential therapeutic targets specific to elderly MS patients and work on their development in the future., This work was supported by the Fondo de Investigaciónes Sanitarias, Instituto de Salud Carlos III, and co-funded by the European Union (European Regional Development Fund/European Social Fund), “A way to build Europe”, under Grant PI18/01146 and the “Agència de Gestió d'Ajuts Universitaris i de Recerca” (AGAUR; Generalitat de Catalunya) under Grant 2021SGR782.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

IL-6 Inhibition as a Therapeutic Target in Aged Experimental Autoimmune Encephalomyelitis

  • Dema Etxezarreta, María
  • Eixarch, Herena
  • Castillo Juárez, Mireia
  • Espejo, Carmen
  • Montalban, Xavier
Ageing; Immunosenescence; Multiple sclerosis, Envelliment; Immunosenescència; Esclerosi múltiple, Envejecimiento; Inmunosenescencia; Esclerosis múltiple, Multiple sclerosis (MS) onset at an advanced age is associated with a higher risk of developing progressive forms and a greater accumulation of disability for which there are currently no effective disease-modifying treatments. Immunosenescence is associated with the production of the senescence-associated secretory phenotype (SASP), with IL-6 being one of the most prominent cytokines. IL-6 is a determinant for the development of autoimmunity and neuroinflammation and is involved in the pathogenesis of MS. Herein, we aimed to preclinically test the therapeutic inhibition of IL-6 signaling in experimental autoimmune encephalomyelitis (EAE) as a potential age-specific treatment for elderly MS patients. Young and aged mice were immunized with myelin oligodendrocyte protein (MOG)35–55 and examined daily for neurological signs. Mice were randomized and treated with anti-IL-6 antibody. Inflammatory infiltration was evaluated in the spinal cord and the peripheral immune response was studied. The blockade of IL-6 signaling did not improve the clinical course of EAE in an aging context. However, IL-6 inhibition was associated with an increase in the peripheral immunosuppressive response as follows: a higher frequency of CD4 T cells producing IL-10, and increased frequency of inhibitory immune check points PD-1 and Tim-3 on CD4+ T cells and Lag-3 and Tim-3 on CD8+ T cells. Our results open the window to further studies aimed to adjust the anti-IL-6 treatment conditions to tailor an effective age-specific therapy for elderly MS patients., This work was funded by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III and co-funded by the European Union (European Regional Development Fund/European Social Fund) “A way to build Europe” under Grant [PI18/01146] and the “Agència de Gestió d’Ajuts Universitaris i de Recerca” (AGAUR; Generalitat de Catalunya) under Grant [2021SGR782].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Immunosenescence in multiple sclerosis: the identification of new therapeutic targets

  • Dema Etxezarreta, Maria Arantza
  • Eixarch Ahufinger, Herena
  • Montalban, Xavier
  • Espejo Ruiz, Carmen
  • Villar, Luisa M
Autoimmunitat; Immunosenescència; Esclerosi múltiple, Autoinmunidad; Inmunosenescencia; Esclerosis múltiple, Autoimmunity; Immunosenescence; Multiple sclerosis, The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase in the life expectancy of the general population and the availability of effective disease-modifying treatments. However, current treatments reduce the frequency of relapses and slow the progression of the disease, but they cannot stop the disability accumulation associated with disease progression. One possible explanation is the impact of immunosenescence, which is associated with the accumulation of unusual immune cell subsets that are thought to have a role in the development of an early ageing process in autoimmunity. Here, we provide a recent overview of how senescence affects immune cell function and how it is involved in the pathogenesis of autoimmune diseases, particularly MS. Numerous studies have demonstrated age-related immune changes in experimental autoimmune encephalomyelitis models, and the premature onset of immunosenescence has been demonstrated in MS patients. Therefore, potential therapeutic strategies based on rejuvenating the immune system have been proposed. Senolytics and regenerative strategies using haematopoietic stem cells, therapies based on rejuvenating oligodendrocyte precursor cells, microglia and monocytes, thymus cells and senescent B and T cells are capable of reversing the process of immunosenescence and could have a beneficial impact on the progression of MS., This work was supported by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III , and co-funded by the European Union ( European Regional Development Fund / European Social Fund ), “A way to build Europe”, under Grant PI18/01146 and RD16/0015/004 and the “ Agència de Gestió d'Ajuts Universitaris i de Recerca ” (AGAUR; Generalitat de Catalunya ) under Grant 2017SGR527 .